Skip to main content
. 2019 Mar 18;9:4797. doi: 10.1038/s41598-019-41402-y

Figure 1.

Figure 1

6-FP pretreatment boosts the MR1-dependent response to exogenously added antigens. (A,B) IFN-γ ELISPOT assay results of BEAS-2B pretreated with 6-FP versus control using (A) Msmeg supernatant as the antigen or (B) Mtb infection as the antigen. The data are pooled from 3 independent experiments. IFN-γ spot forming units (SFU) are plotted. For (A), the difference in the Log EC50 was statistically significant between the curves (P = 0.0198). For (B), the difference in the Log EC50 was not statistically significant between the two curves (P = 0.9629). (C) qPCR of MR1 following pretreatment of BEAS-2B with 6-FP or control. The data are pooled from 2 independent experiments. P = 0.1266 (unpaired two-tailed t-test). (D,E) A549 MR1−/−: MR1GFP were used as in (A,B). The data are pooled from 3 independent experiments. For (D), the difference in the Log EC50 was statistically significant between the two curves (P < 0.0001). For (E), the difference in the Log EC50 was not statistically significant between the two curves (P = 0.6839). (F) IFN-γ ELISPOT assay results of 6-FP pretreatment versus control using 0.1 nM 5-OP-RU (Left) or H37Rv cell wall (Right) as the antigen. Left) P = 0.0087 (unpaired two-tailed t-test). Data are representative of 2 independent experiments. Right) P = 0.0191 for the 25 µg condition and P = 0.0461 for the 12.5 µg condition (unpaired two-tailed t-test). Data are pooled from 2 independent experiments.